While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

lending weight to the hypothesis that the GLP-1 may reduce craving for alcohol and nicotine via a similar mechanism to its ability to reduce food cravings and help people achieve weight loss.

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

Simple Promise's Revolutionary GLP-1 Electrolyte Formula Blends Hydration with Metabolic Support for Real, Sustainable Weight ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link ...

The drug, Mazdutide, is the world's first and currently only GCG/GLP-1 dual receptor agonist targeting both weight loss and ...